Open AccessInhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
Author(s) -
Guo,
Daojun Gong,
Jiamin Zhang,
Min Yu,
B. A. Zhuang
Publication year - 2013
Publication title -
clinical interventions in aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 76
eISSN - 1178-1998
pISSN - 1176-9092
DOI - 10.2147/cia.s45064
Subject(s) - gemcitabine , medicine , pancreatic cancer , combination therapy , in vivo , oncology , antimetabolite , cancer research , pharmacology , chemotherapy , cancer , biology , microbiology and biotechnology
Pancreatic carcinoma possesses one of the highest lethality rates, highest drug-resistance, and highest incidence rates. The objective of this research was to enhance the efficacy and drug-resistance for pancreatic carcinoma by using inhibition of SIRT1 combined with gemcitabine therapy methods.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom